Editas Medicine Inc. (NASDAQ:EDIT) traded down 5.1% on Wednesday . The stock traded as low as $16.74 and last traded at $16.81, with a volume of 171,123 shares. The stock had previously closed at $17.71.

Several equities research analysts have recently weighed in on the stock. Jefferies Group upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Cowen and Company reiterated a “buy” rating on shares of Editas Medicine in a research report on Monday, May 16th. Finally, Vetr raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price on the stock in a research note on Monday, May 9th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.50.

The stock has a 50-day moving average of $22.87 and a 200 day moving average of $29.41. The company’s market cap is $595.50 million.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). On average, equities research analysts predict that Editas Medicine Inc. will post ($2.59) EPS for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.